Consensus-Based Guidelines for the Treatment of Atopic Dermatitis in Korea (Part II): Biologics and JAK inhibitors

• Published in: Annals of dermatology Vol. 37; no. 4; pp. 216 - 227
• Main Authors: Ko, Hyun-Chang, Woo, Yu Ri, Ko, Joo Yeon, Kim, Hye One, Bae, Youin, Seo, Young-Joon, Shin, Min Kyung, Ahn, Jiyoung, Lew, Bark-Lynn, Lee, Dong Hun, Lee, Sang Eun, Lee, Sul Hee, Lee, Yang Won, Lee, Ji Hyun, Jang, Yong Hyun, Jeon, Jiehyun, Choi, Sun Young, Han, Ju Hee, Han, Tae Young, Son, Sang Wook, Cho, Sang Hyun
• Format: Journal Article
• Language: English
• Published: Korea (South) The Korean Dermatological Association; The Korean Society for Investigative Dermatology 01.08.2025; 대한피부과학회
• Subjects: Original; 피부과학; Guideline; Janus Kinase inhibitors; Atopic dermatitis; Biologics; Consensus; Republic of Korea
• ISSN: 1013-9087; 2005-3894; 2005-3894
• DOI: 10.5021/ad.24.154

Atopic dermatitis (AD) is a common skin disease with a wide range of symptoms. Due to the rapidly changing treatment landscape, regular updates to clinical guidelines are needed. This study aimed to update the guidelines for the treatment of AD to reflect recent therapeutic advances and evidence-based recommendations. The Patient characteristics, type of Intervention, Control, and Outcome framework was used to determine 48 questions related to AD management. Evidence was graded, recommendations were determined, and, after 2 voting rounds among the Korean Atopic Dermatitis Association (KADA) council members, consensus was achieved. This guideline provides treatment guidance on advanced systemic treatment modalities for AD. In particular, the guideline offers up-to-date treatment recommendations for biologics and Janus-kinase inhibitors used in the treatment of patients with moderate to severe AD. It also provides guidance on other therapies for AD, along with tailored recommendations for children, adolescents, the elderly, and pregnant or breastfeeding women. KADA's updated AD treatment guidelines incorporate the latest evidence and expert opinion to provide a comprehensive approach to AD treatment. The guidelines will help clinicians optimize patient-specific therapies.